Skip to main content
. 2013 Jul;49(1):86–95. doi: 10.1165/rcmb.2012-0224OC

Figure 1.

Figure 1.

Growth-arrested IMR-90 (white bar; n = 9), CCL-210 (diagonal cross-hatch bars; n = 3), and primary normal (horizontal cross-hatch bars; n = 3) and idiopathic pulmonary fibrosis (IPF) lung fibroblasts (black bars; n = 9) were treated with or without Fas-activating antibodies (Fas-Ab) (250 ng/ml) in the presence or absence of cycloheximide (CHX) (500 ng/ml) for 16 hours, and apoptosis was assessed by ELISA detection of histone-associated DNA fragments. Relative apoptosis is expressed as a percentage of the assay-positive control that was run on the ELISA plate for each experiment. All samples were run in triplicate for each ELISA. The CHX-alone bars represent a subset of experiments for each fibroblast population, including three IMR-90 experiments, two CCL-210 experiments, two primary normal cell lines, and three of the IPF fibroblast cell lines. *P < 0.05 compared with untreated cells of the same cell line. **P < 0.01 compared with untreated cells of the same cell type. #P < 0.05 compared with Fas-Ab–treated IMR-90, CCL-210, and primary normal lung fibroblasts. NS = no statistically significant difference.